MedTrace Logo

A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021)

NCT01717300 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 459

Last updated 2017-04-17

No results posted yet for this study

Summary

This study will evaluate the effects of 2 different dose levels of anacetrapib on low-density lipoprotein-cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) in participants with hypercholesterolemia when added to an existing statin-modifying therapy.

Conditions

Interventions

DRUG

Anacetrapib 100 mg

100 mg tablet, oral, once daily for 24 weeks

DRUG

Placebo for anacetrapib 100 mg

Placebo tablet, orally, once daily for 24 weeks

DRUG

Anacetrapib 25 mg

25 mg tablet, oral, once daily for 24 weeks

DRUG

Placebo for anacetrapib 25 mg

Placebo tablet, orally, once daily for 24 weeks

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-06
Primary Completion
2014-10-29
Completion
2014-10-29

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01717300 on ClinicalTrials.gov